312 related articles for article (PubMed ID: 21800959)
21. Genesis and biology of vestibular schwannomas.
Roche PH; Bouvier C; Chinot O; Figarella-Branger D
Prog Neurol Surg; 2008; 21():24-31. PubMed ID: 18810196
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.
Jacob A; Lee TX; Neff BA; Miller S; Welling B; Chang LS
Otol Neurotol; 2008 Jan; 29(1):58-68. PubMed ID: 18199958
[TBL] [Abstract][Full Text] [Related]
23. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
24. Involvement of p21 (waf1) in merlin deficient sporadic vestibular schwannomas.
Wu H; Chen Y; Wang ZY; Li W; Li JQ; Zhang L; Lu YJ
Neuroscience; 2010 Sep; 170(1):149-55. PubMed ID: 20600642
[TBL] [Abstract][Full Text] [Related]
25. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
[TBL] [Abstract][Full Text] [Related]
26. Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2.
Black FO; Brackmann DE; Hitselberger WE; Purdy J
Am J Otol; 1995 Jul; 16(4):431-43. PubMed ID: 8588642
[TBL] [Abstract][Full Text] [Related]
27. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
28. [Molecular biological analysis of neurofibromatosis type 2 gene].
Ichimura K; Yuasa Y
Nihon Rinsho; 1993 Sep; 51(9):2462-6. PubMed ID: 8411729
[TBL] [Abstract][Full Text] [Related]
29. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.
Torres-Martin M; Lassaletta L; San-Roman-Montero J; De Campos JM; Isla A; Gavilan J; Melendez B; Pinto GR; Burbano RR; Castresana JS; Rey JA
Int J Oncol; 2013 Mar; 42(3):848-62. PubMed ID: 23354516
[TBL] [Abstract][Full Text] [Related]
30. Exploring the "two-hit hypothesis" in NF2: tests of two-hit and three-hit models of vestibular schwannoma development.
Woods R; Friedman JM; Evans DG; Baser ME; Joe H
Genet Epidemiol; 2003 May; 24(4):265-72. PubMed ID: 12687643
[TBL] [Abstract][Full Text] [Related]
31. Immunoblotting analysis of schwannomin/merlin in human schwannomas.
Harwalkar JA; Lee JH; Hughes G; Kinney SE; Golubić M
Am J Otol; 1998 Sep; 19(5):654-9. PubMed ID: 9752976
[TBL] [Abstract][Full Text] [Related]
32. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
[TBL] [Abstract][Full Text] [Related]
34. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
35. Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas.
Shi J; Lu D; Gu R; Xie J; Yu L; Sun X; Zhang Y
World Neurosurg; 2022 Jan; 157():e66-e76. PubMed ID: 34587518
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetics alterations and tumor behavior of sporadic vestibular schwannoma from the People's Republic of China.
Bian LG; Tirakotai W; Sun QF; Zhao WG; Shen JK; Luo QZ
J Neurooncol; 2005 Jul; 73(3):253-60. PubMed ID: 15980976
[TBL] [Abstract][Full Text] [Related]
37. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis of vestibular schwannomas: insights for the development of novel medical therapies.
Miller C; Igarashi S; Jacob A
Otolaryngol Pol; 2012; 66(2):84-95. PubMed ID: 22500497
[TBL] [Abstract][Full Text] [Related]
39. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
[TBL] [Abstract][Full Text] [Related]
40. Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.
Warren C; James LA; Ramsden RT; Wallace A; Baser ME; Varley JM; Evans DG
J Med Genet; 2003 Nov; 40(11):802-6. PubMed ID: 14627667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
